GlassScriptPhysician profile
Laura E Wooten
NPI 1275029258
$1,773.70
in general payments reported to CMS, 2019-2025
12 companies · $599 in 2025
The $599 reported for 2025 was more than what 81% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $307 · 2020: $290 · 2021: $77.26 · 2022: $220 · 2023: $85.58 · 2024: $194 · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $879.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $879.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $534.56 | 2019-2025 | Precision7, Rocklatan, Total30 |
| Johnson & Johnson Vision Care, INC. | $299.21 | 2019-2025 | Acuvue |
| Coopervision INC. | $252.77 | 2019-2025 | Clariti Contact Lens, Myday Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $204.01 | 2019-2020 | |
| Biotissue Holdings INC. | $148.00 | 2021-2025 | |
| Bausch & Lomb Americas INC. | $144.91 | 2023-2025 | Infuse, Vyzulta, Miebo |
| Sun Pharmaceutical Industries INC. | $54.11 | 2025 | |
| Oyster Point Pharma, INC. | $39.92 | 2022 | |
| Eyevance Pharmaceuticals LLC | $34.74 | 2022 | |
| Harrow Eye, LLC | $23.93 | 2025 | Vevye |
| Dompe US, INC. | $20.33 | 2025 | Oxervate |
| Abbvie INC. | $17.21 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Wooten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.